Clinician-patient risk discussion for atherosclerotic cardiovascular disease prevention: Importance to implementation of the 2013 ACC/AHA guidelines

Journal of the American College of Cardiology

Volumn 65, Issue 13, 2015, Pages 1361-1368

  Martin, Seth S ^a   Sperling, Laurence S ^b   Blaha, Michael J ^a   Wilson, Peter W F ^b   Gluckman, Ty J ^a,c   Blumenthal, Roger S ^a   Stone, Neil J ^d  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Providence Heart and Vascular Institute   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Cerebrovascular disease; Coronary heart disease; Lipid lowering therapy; Myocardial infarction; Risk estimation; Shared decision making

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ATHEROSCLEROSIS; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CLINICIAN PATIENT RISK DISCUSSION; COMPUTER PROGRAM; CONCEPTUAL FRAMEWORK; DIABETES MELLITUS; DOCTOR PATIENT RELATION; DRUG EFFICACY; EVIDENCE BASED MEDICINE; HEALTH CARE QUALITY; HUMAN; LIFESTYLE; LONGEVITY; MEDICAL DECISION MAKING; MEDICAL SOCIETY; MEMORY DISORDER; MUSCLE DISEASE; PRACTICE GUIDELINE; PREVENTIVE MEDICINE; PRIMARY PREVENTION; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; WEIGHT CONTROL; DECISION MAKING; FEMALE; MALE; PROCEDURES; RISK REDUCTION; UNITED STATES;

AMERICAN HEART ASSOCIATION; ATHEROSCLEROSIS; DECISION MAKING; FEMALE; GUIDELINES AS TOPIC; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; PHYSICIAN-PATIENT RELATIONS; PRIMARY PREVENTION; RISK ASSESSMENT; RISK FACTORS; RISK REDUCTION BEHAVIOR; UNITED STATES;

EID: 84933073547     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2015.01.043     Document Type: Review

References (50)

1. Stone NJ, Robinson J, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014;63:2889-934.
2. Stone NJ, Robinson JG, Lichtenstein AH, et al., for the 2013 ACC/AHA Cholesterol Guideline Panel. Treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: synopsis of the 2013 American College of Cardiology/American Heart Association cholesterol guideline. Ann Intern Med 2014;160:339-43.
3. Stone NJ, Robinson JG, Lichtenstein A. The new cholesterol treatment guidelines. N Engl J Med 2014;370:1957.
4. Martin SS, Abd TT, Jones SR, Michos ED, Blumenthal RS, Blaha MJ. 2013 ACC/AHA cholesterol treatment guideline: What was done well and what could be done better. J Am Coll Cardiol 2014;63:2674-8.
5. Martin SS, Blumenthal RS. Concepts and controversies: The 2013 American College of Cardiology/American Heart Association risk assessment and cholesterol treatment guidelines. Ann Intern Med 2014;160:356-8.
6. Martin SS, Stone NJ, Blumenthal RS. The Risk Discussion: A Key Virtue of the 2013 ACC/AHA Cholesterol Treatment Guidelines. Cardiology Today [serial online]. January 27, 2014. Available at: http://www.healio.com/cardiology/guidelines/news/online/%7Bb672ff07-1288-4fee-9407-82cb3821a8c9%7D/the-risk-discussion-a-key-virtue-ofthe-2013-accaha-cholesterol-treatment-guidelines. Accessed January, 27, 2015.
7. Barry MJ, Edgman-Levitan S. Shared decision making-pinnacle of patient-centered care. N Engl J Med 2012;366:780-1.
8. Oshima Lee E, Emanuel EJ. Shared decision making to improve care and reduce costs. N Engl J Med 2013;368:6-8.
9. Hess EP, Coylewright M, Frosch DL, Shah ND. Implementation of shared decision making in cardiovascular care: past, present, and future. Circ Cardiovasc Qual Outcomes 2014;7:797-803.
10. Montori VM, Brito JP, Murad MH. The optimal practice of evidence-based medicine: incorporating patient preferences in practice guidelines. JAMA 2013;310:2503-4.
11. Hoffmann TC, Légaré F, Simmons MB, et al. Shared decision making: What do clinicians need to know and why should they bother? Med J Aust 2014;201:35-9.
12. Deber RB, Kraetschmer N, Irvine J. What role do patients wish to play in treatment decision making? Arch Int Med 1996;156:1414-20.
13. Adams JR, Elwyn G, Légaré F, Frosch DL. Communicating with physicians about medical decisions: A reluctance to disagree. Arch Intern Med 2012;172:1184-6.
14. Krumholz HM, Barreto-Filho JA, Jones PG, Li Y, Spertus JA. Decision-making preferences among patients with an acute myocardial infarction. JAMA Intern Med 2013;173:1252-7.
15. Mann DM, Ponieman D, Montori VM, Arciniega J, McGinn T. The Statin Choice decision aid in primary care: A randomized trial. Patient Educ Couns 2010;80:138-40.
16. American College of Cardiology. ASCVD Risk Estimator [mobile application]. iTunes. February 22, 2014. Available at: https://itunes.apple.com/us/app/ascvd-risk-estimator/id808875968?mt=8. Accessed January 27, 2015.
17. American College of Cardiology Foundation. ASCVD Risk Estimator [mobile application]. Google Play. February 3, 2014. Available at: https://play.google.com/store/apps/details?id=org.acc.cvrisk&hl=en. Accessed January 27, 2015.
18. American College of Cardiology, American Heart Association. ASCVD Risk Estimator [online tool]. 2014. Available at: http://tools.cardiosource.org/ASCVD-Risk-Estimator/Accessed January 27, 2015.
19. Eckel RH, Jakicic JM, Ard JD, et al. 2013 AHA/ACC guideline on lifestyle management to reduce cardiovascular risk: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014;63:2960-84.
20. Jensen MD, Ryan DH, Apovian CM, et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Obesity Society. J Am Coll Cardiol 2014;63: 2985-3023.
21. Goff DC Jr., Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014;63:2935-59.
22. Mayo Clinic. Statin/Aspirin Choice Decision Aid [online tool]. July 13, 2013. Available at: http://statindecisionaid.mayoclinic.org/Accessed January 27, 2015.
23. Zipkin DA, Umscheid CA, Keating NL, et al. Evidence-based risk communication: A systematic review. Ann Intern Med 2014;161:270-80.
24. Fontana M, Asaria P, Moraldo M, et al. Patientaccessible tool for shared decision making in cardiovascular primary prevention: balancing longevity benefits against medication disutility. Circulation 2014;129:2539-46.
25. Czarny MJ, Martin SS, Kohli P, Metkus T, Blumenthal RS. Nonfatal outcomes in the primary prevention of atherosclerotic cardiovascular disease: is all-cause mortality really all that matters? Circ Cardiovasc Qual Outcomes 2014;7:481-5.
26. O'Sullivan AK, Rubin J, Nyambose J, Kuznik A, Cohen DJ, Thompson D. Cost estimation of cardiovascular disease events in the US. Pharmacoeconomics 2011;29:693-704.
27. Stacey D, Légaré F, Col NF, et al. Decision aids for people facing health treatment or screening decisions. Cochrane Database Syst Rev 2014;1: CD001431.
28. Barry MJ. Health decision aids to facilitate shared decision making in office practice. Ann Intern Med 2002;136:127-35.
29. Trevena LJ, Zikmund-Fisher BJ, Edwards A, et al. Presenting quantitative information about decision outcomes: A risk communication primer for patient decision aid developers. BMC Med Inform Decis Mak 2013;13 Suppl 2:S7.
30. Katz DH, Intwala SS, Stone NJ. Addressing statin adverse effects in the clinic: The 5 Ms. J Cardiovasc Pharmacol Ther 2014;19:533-42.
31. Ridker PM, Pradhan A, MacFadyen JG, Libby P, Glynn RJ. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: An analysis from the JUPITER trial. Lancet 2012;380: 565-71.
32. Waters DD, Ho JE, Boekholdt SM, et al. Cardiovascular event reduction versus new-onset diabetes during atorvastatin therapy: Effect of baseline risk factors for diabetes. J Am Coll Cardiol 2013;61:148-52.
33. Nielsen SF, Nordestgaard BG. Statin use before diabetes diagnosis and risk of microvascular disease: A nationwide nested matched study. Lancet Diabetes Endocrinol 2014;2:894-900.
34. Knowler WC, Barrett-Connor E, Fowler SE, et al., for the Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403.
35. Ong KL, Waters DD, Messig M, DeMicco DA, Rye KA, Barter PJ. Effect of change in body weight on incident diabetes mellitus in patients with stable coronary artery disease treated with atorvastatin (from the Treating to New Targets study). Am J Cardiol 2014;113:1593-8.
36. Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes: A collaborative metaanalysis of randomised statin trials. Lancet 2010; 375:735-42.
37. Cannon CP. Balancing the benefits of statins versus a new risk-diabetes. Lancet 2010;375: 700-1.
38. Swiger KJ, Manalac RJ, Blumenthal RS, Blaha MJ, Martin SS. Statins and cognition: A systematic review and meta-analysis of short- And long-term cognitive effects. Mayo Clin Proc 2013; 88:1213-21.
39. Richardson K, Schoen M, French B, et al. Statins and cognitive function: A systematic review. Ann Intern Med 2013;159:688-97.
40. Jukema JW, Cannon CP, de Craen AJ, Westendorp RG, Trompet S. The controversies of statin therapy: Weighing the evidence. J Am Coll Cardiol 2012;60:875-81.
41. Mampuya WM, Frid D, Rocco M, et al. Treatment strategies in patients with statin intolerance: The Cleveland Clinic experience. Am Heart J 2013; 166:597-603.
42. Zhang H, Plutzky J, Skentzos S, et al. Discontinuation of statins in routine care settings: A cohort study. Ann Intern Med 2013;158: 526-34.
43. Mizuno K, Nakaya N, Ohashi Y, et al., for the MEGA Study Group. Usefulness of pravastatin in primary prevention of cardiovascular events in women: Analysis of the Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA study). Circulation 2008; 117:494-502.
44. Mora S, Glynn RJ, Hsia J, MacFadyen JG, Genest J, Ridker PM. Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia: results from the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) and metaanalysis of women from primary prevention trials. Circulation 2010;121:1069-77.
45. Henriquez AR. Bias control in shared decision making: still too many loose ends. BMJ 2012;345: E8291.
46. Elwyn G, Scholl I, Tietbohl C, et al. "Many miles to go.": A systematic review of the implementation of patient decision support interventions into routine clinical practice. BMC Med Inform Decis Mak 2013;13 Suppl 2:S14.
47. Frosch DL, May SG, Rendle KA, Tietbohl C, Elwyn G. Authoritarian physicians and patients' fear of being labeled 'difficult' among key obstacles to shared decision making. Health Aff (Millwood) 2012;31:1030-8.
48. Mulley AG, Trimble C, Elwyn G. Stop the silent misdiagnosis: patients' preferences matter. BMJ 2012;345:e6572.
49. Akincigil A, Bowblis JR, Levin C, Jan S, Patel M, Crystal S. Long-term adherence to evidence based secondary prevention therapies after acute myocardial infarction. J Gen Intern Med 2008;23:115-21.
50. Pronovost PJ. Enhancing physicians' use of clinical guidelines. JAMA 2013;310:2501-2.